ID

37243

Descrizione

Registry for Analysis of Compliance in Colombian Participants With Rheumatoid Arthritis Exposed to Golimumab; ODM derived from: https://clinicaltrials.gov/show/NCT02414984

collegamento

https://clinicaltrials.gov/show/NCT02414984

Keywords

versioni (1)
  1. 11/07/19 11/07/19 -
Titolare del copyright

See clinicaltrials.gov

Caricato su

11 luglio 2019

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Rheumatoid Arthritis NCT02414984

Inglese

Eligibility Rheumatoid Arthritis NCT02414984

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
participants with moderate to severe ra for whom the physician had decided to treat with golimumab according to the local product label, with the first dose being administered between 12 and 26 weeks prior to study enrollment
Descrizione

Rheumatoid Arthritis Moderate | Rheumatoid Arthritis Severe | golimumab

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0003873
UMLS CUI [1,2]
C0205081
UMLS CUI [2,1]
C0003873
UMLS CUI [2,2]
C0205082
UMLS CUI [3]
C2353893
participants who have achieved an adequate therapeutic response to regular doses of golimumab, within 12 to 26 weeks of treatment
Descrizione

Fair therapeutic response | Golimumab Dose Regular

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0184784
UMLS CUI [2,1]
C2353893
UMLS CUI [2,2]
C0178602
UMLS CUI [2,3]
C0205272
participants should be evaluated for tuberculosis (tb) exposure/risk factors or managed for active and latent tb (per local requirements and according to the local product label)
Descrizione

Evaluation Exposure to Tuberculosis | Evaluation Exposure to Risk factors | Management Tuberculosis | Management Latent Tuberculosis

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1261322
UMLS CUI [1,2]
C0332157
UMLS CUI [1,3]
C0041296
UMLS CUI [2,1]
C1261322
UMLS CUI [2,2]
C0332157
UMLS CUI [2,3]
C0035648
UMLS CUI [3,1]
C0376636
UMLS CUI [3,2]
C0041296
UMLS CUI [4,1]
C0376636
UMLS CUI [4,2]
C1609538
participants who have been evaluated for active/latent hepatitis b virus (hbv) and hepatitis c virus (hcv)
Descrizione

Evaluation Hepatitis B Virus | Evaluation Hepatitis B Virus Latent | Evaluation Hepatitis C virus | Evaluation Hepatitis C virus Latent

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1261322
UMLS CUI [1,2]
C0019169
UMLS CUI [2,1]
C1261322
UMLS CUI [2,2]
C0019169
UMLS CUI [2,3]
C0205275
UMLS CUI [3,1]
C1261322
UMLS CUI [3,2]
C0220847
UMLS CUI [4,1]
C1261322
UMLS CUI [4,2]
C0220847
UMLS CUI [4,3]
C0205275
participants for whom, since golimumab initiation, a complete medical record is available
Descrizione

Availability of Medical Record Complete

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0470187
UMLS CUI [1,2]
C0025102
UMLS CUI [1,3]
C0205197
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
participants who have received and terminated golimumab treatment in the past
Descrizione

Golimumab Treatment completed In the past

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C2353893
UMLS CUI [1,2]
C0580352
UMLS CUI [1,3]
C1444637
participants that have been treated with golimumab for more than 26 weeks prior to enrolment in the study
Descrizione

Golimumab Duration of treatment | Status pre- Enrollment

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C2353893
UMLS CUI [1,2]
C0444921
UMLS CUI [2,1]
C0332152
UMLS CUI [2,2]
C1516879
participants with use of any other investigational agent less than or equal to 30 days before starting treatment with golimumab
Descrizione

Investigational New Drugs

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0013230
participants with suspected latent tb, having not received prophylactic treatment of at least 4 weeks
Descrizione

Latent Tuberculosis Suspected | Prophylactic treatment Duration Absent

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1609538
UMLS CUI [1,2]
C0750491
UMLS CUI [2,1]
C0199176
UMLS CUI [2,2]
C0449238
UMLS CUI [2,3]
C0332197
participants with suspected or active tb
Descrizione

Tuberculosis Suspected | Tuberculosis

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0041296
UMLS CUI [1,2]
C0750491
UMLS CUI [2]
C0041296
participants with active/latent hbv or hcv
Descrizione

Hepatitis B Virus | Hepatitis C virus | Hepatitis B Virus Latent | Hepatitis C virus Latent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0019169
UMLS CUI [2]
C0220847
UMLS CUI [3,1]
C0019169
UMLS CUI [3,2]
C0205275
UMLS CUI [4,1]
C0220847
UMLS CUI [4,2]
C0205275
Ritorna all'inizio della pagina

Similar models

Eligibility Rheumatoid Arthritis NCT02414984

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Rheumatoid Arthritis Moderate | Rheumatoid Arthritis Severe | golimumab
Item
participants with moderate to severe ra for whom the physician had decided to treat with golimumab according to the local product label, with the first dose being administered between 12 and 26 weeks prior to study enrollment
boolean
C0003873 (UMLS CUI [1,1])
C0205081 (UMLS CUI [1,2])
C0003873 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C2353893 (UMLS CUI [3])
Fair therapeutic response | Golimumab Dose Regular
Item
participants who have achieved an adequate therapeutic response to regular doses of golimumab, within 12 to 26 weeks of treatment
boolean
C0184784 (UMLS CUI [1])
C2353893 (UMLS CUI [2,1])
C0178602 (UMLS CUI [2,2])
C0205272 (UMLS CUI [2,3])
Evaluation Exposure to Tuberculosis | Evaluation Exposure to Risk factors | Management Tuberculosis | Management Latent Tuberculosis
Item
participants should be evaluated for tuberculosis (tb) exposure/risk factors or managed for active and latent tb (per local requirements and according to the local product label)
boolean
C1261322 (UMLS CUI [1,1])
C0332157 (UMLS CUI [1,2])
C0041296 (UMLS CUI [1,3])
C1261322 (UMLS CUI [2,1])
C0332157 (UMLS CUI [2,2])
C0035648 (UMLS CUI [2,3])
C0376636 (UMLS CUI [3,1])
C0041296 (UMLS CUI [3,2])
C0376636 (UMLS CUI [4,1])
C1609538 (UMLS CUI [4,2])
Evaluation Hepatitis B Virus | Evaluation Hepatitis B Virus Latent | Evaluation Hepatitis C virus | Evaluation Hepatitis C virus Latent
Item
participants who have been evaluated for active/latent hepatitis b virus (hbv) and hepatitis c virus (hcv)
boolean
C1261322 (UMLS CUI [1,1])
C0019169 (UMLS CUI [1,2])
C1261322 (UMLS CUI [2,1])
C0019169 (UMLS CUI [2,2])
C0205275 (UMLS CUI [2,3])
C1261322 (UMLS CUI [3,1])
C0220847 (UMLS CUI [3,2])
C1261322 (UMLS CUI [4,1])
C0220847 (UMLS CUI [4,2])
C0205275 (UMLS CUI [4,3])
Availability of Medical Record Complete
Item
participants for whom, since golimumab initiation, a complete medical record is available
boolean
C0470187 (UMLS CUI [1,1])
C0025102 (UMLS CUI [1,2])
C0205197 (UMLS CUI [1,3])
Item Group
C0680251 (UMLS CUI)
Golimumab Treatment completed In the past
Item
participants who have received and terminated golimumab treatment in the past
boolean
C2353893 (UMLS CUI [1,1])
C0580352 (UMLS CUI [1,2])
C1444637 (UMLS CUI [1,3])
Golimumab Duration of treatment | Status pre- Enrollment
Item
participants that have been treated with golimumab for more than 26 weeks prior to enrolment in the study
boolean
C2353893 (UMLS CUI [1,1])
C0444921 (UMLS CUI [1,2])
C0332152 (UMLS CUI [2,1])
C1516879 (UMLS CUI [2,2])
Investigational New Drugs
Item
participants with use of any other investigational agent less than or equal to 30 days before starting treatment with golimumab
boolean
C0013230 (UMLS CUI [1])
Latent Tuberculosis Suspected | Prophylactic treatment Duration Absent
Item
participants with suspected latent tb, having not received prophylactic treatment of at least 4 weeks
boolean
C1609538 (UMLS CUI [1,1])
C0750491 (UMLS CUI [1,2])
C0199176 (UMLS CUI [2,1])
C0449238 (UMLS CUI [2,2])
C0332197 (UMLS CUI [2,3])
Tuberculosis Suspected | Tuberculosis
Item
participants with suspected or active tb
boolean
C0041296 (UMLS CUI [1,1])
C0750491 (UMLS CUI [1,2])
C0041296 (UMLS CUI [2])
Hepatitis B Virus | Hepatitis C virus | Hepatitis B Virus Latent | Hepatitis C virus Latent
Item
participants with active/latent hbv or hcv
boolean
C0019169 (UMLS CUI [1])
C0220847 (UMLS CUI [2])
C0019169 (UMLS CUI [3,1])
C0205275 (UMLS CUI [3,2])
C0220847 (UMLS CUI [4,1])
C0205275 (UMLS CUI [4,2])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial